摘要
目的:探讨血清AFP、VEGF及HSP70 在原发性肝癌中的表达及对预后的预测价值.方法:选择 110 例原发性肝癌、50例健康体检者分别为研究组、对照组,根据术后 1年内预后情况将研究组分为预后良好组和预后不良组,对比血清AFP、VEGF及HSP70表达差异,评价其对预后不良的诊断效能.结果:研究组血清AFP、VEGF及HSP70高于对照组,预后不良组高于预后良好组(P＜0.05);血清AFP、VEGF及HSP70预测原发性肝癌患者预后不良的AUC为 0.981.结论:血清AFP、VEGF及HSP70可预测原发性肝癌患者预后不良.
Abstract
Objective:To investigate the expression of serum AFP,VEGF,and HSP70 in primary liver cancer and their predictive value for prognosis.Method:110 cases of primary liver cancer and 50 healthy individuals were selected as the study group and control group,respectively.Based on the prognosis within one year after surgery,the study group was divided into a good prognosis group and a poor prognosis group.The differences in serum AFP,VEGF,and HSP70 expression were compared to evaluate their diagnostic efficacy for poor prognosis.Result:The serum levels of AFP,VEGF,and HSP70 in the study group were higher than those in the control group,and those in the poor prognosis group were higher than those in the good prognosis group(P<0.05);The AUC for predicting poor prognosis in patients with primary liver cancer using serum AFP,VEGF,and HSP70 is 0.981.Conclusion:Serum AFP,VEGF,and HSP70 can predict poor prognosis in patients with primary liver cancer.
国家科技期刊平台
NSTL
万方数据